Drug Profile
GR 328713
Alternative Names: GW 328713Latest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antihyperlipidaemics
- Mechanism of Action Microsomal triglyceride transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 16 Jul 1999 Discontinued-I for Hypercholesterolaemia in United Kingdom (Unknown route)
- 07 Jul 1999 No-Development-Reported for Hypercholesterolaemia in United Kingdom (Unknown route)
- 26 Jun 1998 Phase-I clinical trials for Hypercholesterolaemia in United Kingdom (Unknown route)